Fig. 1

Functional, molecular architecture of AVEC: anti-HER-2 × HBsAg. The architecture of antibody vaccine engineered constructs (AVEC: anti-HER-2 × HBsAg) is shown. AVEC consist of the effector domains: HBsAg, FcR-BD, C1q-BD and the targeting domains: anti-HER-2 CDRs. HBsAg: human hepatitis B virus surface antigen vaccine; it is the hepatitis B virus like particle (VLP) vaccine, which engages native and stimulates development of adaptive arms of immunity, upon vaccination both arms are engaged as prophylactic immunity against the hot hepatitis B virus. FcR- BD: a crystallizable fragment of the antibody (Fc) is its binding domain for FcR receptors (FcR), i.e., a ligand for FcR; as it is thus anchoring all FcR displaying cells: natural killer cells, dendritic cells and after presenting antigens by APCs by cytotoxic lymphocytes (CTL), B lymphocytes, macrophages, neutrophils, basophils, eosinophils, mast cells, and others. C1q-BD: it is a docking site for C1q element of the complement system cascade (C1q) leading to its main effector C3 leading to assembly of the complex and perforation of the cell membranes. Anti-HER-2 CDR: human epithelial cell receptor 2 complementarity determining regions of light (anti-HER-2–LC) and heavy (anti-HER 2–HC CDR) chains of the antibody guide the AVEC to the overexpressed HER-2+ displaying cancer cells